Fineline Cube

Follow:
14691 Articles
Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK's Pipeline
CompanyDeals

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK’s Pipeline

GeneScience Pharmaceuticals' 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT
CompanyDrug

GeneScience Pharmaceuticals’ 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT

Daiichi Sankyo's DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer
CompanyDrug

Daiichi Sankyo’s DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension
CompanyDeals

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71
CompanyDeals

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Innovent Biologics' Xinbimin Meets Primary Endpoint in Phase III RESTORE‑3 Trial – Significant Proptosis Improvement in Chinese Patients with Inactive Thyroid Eye Disease
CompanyDrug

Innovent Biologics’ Xinbimin Meets Primary Endpoint in Phase III RESTORE‑3 Trial – Significant Proptosis Improvement in Chinese Patients with Inactive Thyroid Eye Disease

Chugai Pharmaceutical and InxMed Sign Worldwide License Agreement for SPYK04 – RAF‑MEK Molecular Glue Candidate for Solid Tumors
CompanyDeals

Chugai Pharmaceutical and InxMed Sign Worldwide License Agreement for SPYK04 – RAF‑MEK Molecular Glue Candidate for Solid Tumors

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor
CompanyDeals

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor

OBiO Technology and Renyuan Biotechnology Forge Deep Strategic Collaboration – Advancing EPC Cell Therapy from Preclinical CMC to IND Filing
CompanyDeals

OBiO Technology and Renyuan Biotechnology Forge Deep Strategic Collaboration – Advancing EPC Cell Therapy from Preclinical CMC to IND Filing

Anke Biotechnology Signs Strategic AI Collaboration with DP Technology – Partnering on Intelligent Design of ADC Payload Molecules
CompanyDeals

Anke Biotechnology Signs Strategic AI Collaboration with DP Technology – Partnering on Intelligent Design of ADC Payload Molecules

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment
CompanyDrug

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment